Plasma protein solutions and synthetic plasma substitutes have an established role in therapy in many areas of clinical medicine. Although there have been many advances in the field of plasma volume expanders, an effective, stable, readily available and economical solution, free from side effects remains elusive. In particular, all plasma volume expanders may be associated with a small, but significant incidence of side effects. Allergic and anaphylactoid reactions are the most feared, but questions about prolonged storage and effects on haemostasis and renal function should be considered. Plasma protein fraction may be associated with hypotension, probably due to kinin activation. In the fully conscious patient, features of vasodilatation including flushing, fullness in the head, nasal stuffiness, may also be noted. There have also been reports of true anaphylactic type reactions occurring in atopic subjects after the infusion of small amounts of plasma protein solution. Modified fluid gelatins are well known to release histamine when infused rapidly. The reactions are usually confined to the skin and present clinically as pruritis, urticaria or flushing. There are also reports of anaphylactic reactions not related to dosage which are probably immune in origin. The dextrans are well recognised to cause such anaphylactoid reactions. Accepting that anaphylactoid and anaphylactic reactions may occur in association with plasma volume expanders, anticipation, diagnosis and rapid institution of therapy determine the outcome of these reactions.
INTRODUCTION
There are numerous situations in clinical medicine where the rapid infusion of a plasma protein or synthetic plasma substitute is indicated. Controversy still exists in many such situations as to the relative merits of crystalloid and colloid solutions, but apart from all other considerations there is little doubt that colloid solutions are more effective in correcting deficiencies in blood volume. development of satisfactory plasma volume expanders (PVE) has been the demands imposed by war and civil disaster. Plasma volume expanders have also assumed importance in modern hospital and paramedical practice.
Their specific role may be summarised as: 1. conserving donor blood usage by providing volume replacement, or deliberate haemodilution.
providing intravascular expansion where
blood is not available. 3. replacement of plasma losses, i.e. anaphylaxis, plasmapheresis. 4. allowing time for full crossmatching or collection of blood. Table 1. A. Plasma protein fractions: The standard solution used in Australia is Stable Plasma Protein Solution 5!IJo (SPPS). This is prepared by fractionation and pasteurisation from human plasma. The processing is expensive but the product is supplied free in Australia by the Commonwealth Serum Laboratories. The plasma half life is not accurately known, but is probably longer than that of synthetic colloids. B. Fresh frozen plasma: The use of fresh frozen plasma has been largely superseded by SPPS, but it has the advantage of contalnmg factors V and VIII, gammaglobulins, and the still theoretical advantage of containing opsonins. These advantages are offset by the high sodium concentration and risk of hepatitis.
C. Albumins: Albumin 25!IJo is the most expensive and limited fluid and should be reserved for use as volume replacement where colloid osmotic pressure is low, and its hyperoncotic effect is indicated to promote movement of fluid from extravascular to vascular compartments. D. Modified gelatins: The gelatin solution available in Australia is Haemaccel. Modified gelatins 1 are prepared by heat denaturation or chemical hydrolysis followed by coupling of molecules into larger complexes by reacting them with polycarboxylic acid anhydrides such as succinic anhydride. This modified fluid gelatin can be suspended in isotonic saline. Haemaccel is 3.5!IJo modified fluid gelatin prepared by cross-linkage with diisocyanate. E. Dextrans: The dextrans have been used in clinical medicine for over 30 years. Initially dextran was developed as a plasma volume expander, but subsequently, much interest has been shown in its flow-promoting effects. Dextran is produced by the action of the bacterium Leuconostoc mesenteroides on sucrose. The native dextrans produced have a high molecular weight and have to undergo partial acid hydrolysis to be made suitable for clinical use. Dextran basically consists of a long string of glucose units linked together by alpha 1-6 bonds. At intervals of about 20 glucose units, short side chains of one or two further glucose residues are linked by an alpha 1-3 linkage. Dextran 70 (Macrodex) with a molecular weight of 70,000 is the commonly used volume expander. Dextran 40 (Rheomacrodex) with a molecular weight of 40,000 is predominantly used for its flow-promoting properties. The high molecular weight dextrans are rarely used therapeutically but dextran 150, which has marked rouleaux- 
Fluid overload
Fluid overload is a significant cause of preventable death due to drugs. 3 Fluid overload is essentially due to inappropriate monitoring and administration rather than an inherent property of any particular solution, although SPPS may carry a higher risk than others (vide infra). Because these solutions largely remain intravascular, conventional monitoring of the circulatory system is more reliable than with crystalloids, but conversely, overload with colloids is much more difficult to treat than crystalloid overload.
Contamination and infection
All available volume expanders will support bacterial growth. The risk of infection is less than that of whole blood.
A/lergic and anaphylactoid reactions
The terms anaphylactic and anaphylactoid describe reactions which are clinically indistinguishable and are due to the release of vasoactive mediators from mast cells and basophils. The predominant substance involved is histamine, but in other reactions the Anaesthesia and Intensive Care. Vol. VlI!, No. 2, May, 1980 kallikrein-kinin system may be predominant. The term anaphylaxis implies a Type I IgE reaginic antibody mediated reaction and anaphylactoid is used to describe non-reaginic antibody mediated reactions, and reactions where the mechanism is not proven.
Incidence: The most recent and probably the most comprehensive survey of the incidence of anaphylactoid reactions to plasma volume expanders is by Ring and Messmer. 3 The authors attempted to grade the severity of reactions ( Table 2 ), and found that the incidence of severe reactions to plasma protein solutions was 0.003070, to dextran solution 0.008070 and to gelatin solutions 0.038070 and to hydroxyethyl starch 0.006070. In a twelve year period in Australia 21 reactions were reported. 4 Most authorities believe the true rate is considerably higher than the reported rate 5 and concern about the incidence of reactions does affect the choice of a plasma volume expander. 6 Predisposing factors: (a) Level of consciousness and cardiovascular status. It is well accepted that reactions to volume expanders are more common in fully conscious, normovolaemic or moderately volume depleted patients. Lorenz and Doenicke 7 produced reactions in 60070 of volunteers with rapid infusion. Awake patients will report subjective sensations which are missed in unconscious patients; indeed almost all patients who undergo anaphylaxis have a particular individualized aura or set of subjective feelings. Hypotension during rapid infusion in a hypovolaemic patient is likely to be interpreted as further loss, and particularly with SPPS, which consistently produces a transient fall in blood pressure, a situation fraught with risk of overload can be produced.
(b) Sex
Reactions to dextrans appear more common in males. Women in the perinatal period may be more susceptible to Haemaccel. (c) Batch variation Different batches of haemaccel and dextrans may produce variable amounts of histamine release 7 and the manufacture of SPPS could lead to different amounts of prekallikrein activator.
(d) Atopic and allergic disease
Atopic patients are more susceptible to the effects of histamine and may release more histamine in response to a given stimulus. The incidence of reactions is higher in such patients.
(e) Medication
Beta-blockers, antihistamines, corti costeroids, and vasodilators may interfere with response to stimulus and ability to compensate.
(f) Rate of infusion
Increasing volume, concentration and rate of infusion increases direct histamine release and may increase the degree of hypotension with SPPS.
(g) Patient factors
Pre-existing autoimmune disease,s circulating levels of inactivators such as carboxypeptidase B and histamine, and antidextran antibodies will modify reactivity.
The mechanism of reaction SPPS
Torda et al. 9 and Bland et al. 10 first reported plasma protein fractions as causing hypotension during cardiopulmonary bypass. There have subsequently been reports of hypotension occurring in other clinical situations including plasma exchange. 11 Plasma exchange is an ideal therapeutic situation in which to assess the reaction to plasma volume expanders, as it provides a unique set of circumstances in which plasma volume expanders are being infused at rapid rates (equal to that of resuscitation) into normovolaemic, normotensive and fully conscious patients. All subjective and objective features can be clearly noted. Isbister and Biggsll in 1976 first documented many of the clinical features of reactions to the rapid infusion of plasma protein fraction (SPPS) which included flushing, fullness in the head, nasal stu ffiness, constricting chest pain, abdominal pain, back pain, apprehension and hypotension. These features are similar to those obtained when bradykinin is infused into man. It has subsequently been shown by several workers that some preparations of plasma protein fraction contain high levels of kinin activity which may be responsible for these reactions in some cases. 12 ,13 However, removal of this kinin activity did not lead to a reduction in the incidence of reactions. Recent studies l4 have established that many batches of plasma protein solution contained prekallikrein activator (Hageman factor fragments) which may be responsible for endogenous activation of the kallikrein-kinin system following intravenous infusion of these solutions. IS
The varying amounts of prekallikrein activator in plasma protein fraction is probably determined by the origin and nature of the original plasma used as well as the preparative technique. It is likely that this prekallikrein activator contamination can be removed during manufacture and hopefully these reactions of the kinin type will be eliminated. It is interesting that there have been few reports of kinin reactions in association with albumin infusion and it would appear that most of the prekallikrein activator activity is removed in the fractionation step between plasma protein fraction and purified albumin.
Olinger et al. 16 have recently produced evidence that sodium acetate in plasma protein solutions may be causing the vasodilator reactions. This substance is used as a buffer and is not present in significant amounts in albumin preparations. Although most reactions to plasma protein solutions are kinin in nature there are several reports of true anaphylactic reactions occurring in atopic subjects after the infusion of small amounts. These reactions have, in one series, been attributed to aggregated albuminY,18
Haemaccel
Rapid infusion of Haemaccel is associated with histamine release in most people. Lorenz et al. 19 have shown that the reactions can be completely blocked by HI and H2 antihistamines, suggesting that histamine is the sole mediator. The majority of reactions are Anaesthesia and Intensive Care, Vol. VJJl , No. 2, May, 1980 probably a direct effect, but antibody related reactions occasionally occur and may be related to mediator activation by gelatin-antigelatin immune complexes. Dextrans Low molecular weight dextrans used clinically cannot induce antibody formation but can react with pre-existing antidextran antibodies which are probably stimulated by polysaccharides from microorganisms. 20 They are of the IgG and IgM class and there is no evidence of IgE activity to dextrans.
The presence of anti-dextran antibodies does not correlate well with the occurrence of anaphylactoid reactions. The reactions are not dose-related and usually occur following infusion of the first few millilitres. Although the presence of anti-dextran antibodies is probably required in the plasma for a reaction to occur, there are a number of other factors necessary for a severe dextran-induced anaphylactoid reaction to occur. The nature of these other predisposing factors remains unclear. A previous atopic history appears significant in the milder reactions. Features of histamine release may occur but the more typical features are those of kinin activity and fatal reactions have occurred without elevation of histamine levels. Sudden apprehension, vasodilation, chest pain, abdominal pain and back pain may occur. There is evidence that dextran can activate the alternate pathway of the complement system. Plasma complement levels have been shown to be reduced in some severe cases. Cleavage products of C2, C3 and C5 may be responsible for some of the histamine and kinin activity.
Hydroxyethyl starch
Initial reports suggest that HES does not cause histamine release and has a lower rate of reactions than dextrans. Clinically, the reactions are similar to dextran reactions. Prevention
In high risk patients pretreatment with steroids and antihistamines will prevent anaphylaxis ,7 and with HI and H2 blockers direct histamine release reactions are prevented. However, the incidence is low and the mechanism for each solution varies, and in practical terms prevention is not possible. Some hope has recently occurred with the dextrans, where it has been shown that dextran of mol wt Anaesthesia and Intensive Care, Vol. VIlI, No. 2, May, 1980 lOOO may block clinically significant anaphylactoid reactions in animals (Messmer 1978, personal communication). Initial trials in humans appear to confirm this and it is likely that there will be renewed interest in the dextrans.
Treatment
Anticipation, diagnosis and rapid institution of therapy determine the outcome of severe anaphylactoid reactions to plasma volume expanders. In addition to the usual principles of resuscitation such as stopping infusion, cardiac massage, artificial ventilation and oxygen administration, specific treatment is indicated. The kinin reactions induced by plasma protein solutions resolve rapidly following cesssation of infusion and infusion of an alternative plasma volume expander. Occasionally, a vasoconstrictor (vide infra) may be indicated.
(a) Angioneurotic oedema
The airway should be protected by intubation if necessary. Intramuscular adrenaline 1: 1000 0.5 ml will stop progression of angioedema. Antihistamines should then be given as angioedema may recur.
(b) Cardiovascular collapse
The collapse is due to vasodilatation, loss of plasma volume and possibly reduced cardiac performance, either consequent upon mediator effects or hypoxia. Vasoconstrictor drugs should be used and most authors advocate adrenaline as the drug of choice. Recently Whitwam 21 has advocated angiotensin as a smooth muscle stimulator but the authors believe adrenaline should be preferred as it improves cardiac function and reduces mediator release, reduces bronchial tone and has been proven clinically as opposed to angiotensin.
In addition plasma volume must be restored with large volumes of an alternative colloid solution, up to 2 litres. Crystalloids are ineffective 22 and if response to adrenaline is not dramatic it can be assumed that hypovolaemia is present and infusion commenced immediately. Antihistamines are of no benefit.
Steroids have no proven role in experimental or human anaphylaxis 7 but there is anecdotal evidence to support their use. In lifethreatening situations there is a case for using high dose steroid but it is not a drug of first choice.
(c) Bronchospasm
Adrenaline is the drug of first choice. Bronchospasm is the most severe complication and usually present in fatal cases. All other remedies should be tried, such as isoprenaline, salbutamol, procaine, halothane, ether and ketamine.
(d) Follow up
In view of the difficulty in determining the precise nature of the reaction and the availability of alternatives, all patients who have severe reactions should receive full advice as to the reaction and be encouraged to wear Medic Alert bracelets.
Incomplete metabolism and storage
Hydroxyethyl starch has been shown to partially persist in the body for years (Messmer
1978, personal communication). This gives rise
to concern about possible carcinogenicity.
Effects of haemostasis
It has been known for many years that the dextrans have unique effects on the haemostatic system which may cause significant haemostatic failure if excessive amounts are infusedY However, the flow-promoting and antithrombotic effects of dextran may have considerable potential. Numerous effects on the vascular, platelet, coagulation and fibrinolytic phases of haemostasis, have all been described. Recent work suggests that dextran induces an acquired von Willebrand's state. It appears that dextran must circulate for a few hours before these changes can be clearly demonstrated and many of the effects are not demonstrable by direct in vitro mixing. As long as the total dose used remains less than 1500 ml (or 1.5 g/kg body weight) clinically significant disturbance of haemostasis is unlikely, but the potential benefits of its antithrombotic action should be considered. Many haematologists have stated that a substance which produced acquired von Willebrand's disease and improved microcirculatory flow would be an ideal antithrombotic agent.
Effects on renal function
Dextran 40 has been implicated as causing acute renal failure. Dextran 40 infusion results in histological changes in the renal tubulesY These changes are reversible as long as urinary output is maintained. There is no good evidence that dextran 70 may be responsible for the development of acute renal failure.
Effects on crossmatching techniques
There has been much controversy over the years regarding the effects of the various plasma volume expanders on interpretation of crossmatching tests. Many of the early plasma volume expanders, particularly the high molecular weight dextrans, did have marked rouleaux-inducing effects on red cells which made interpretation of the saline crossmatch rather difficult. 25 Much of the dogma from this era has carried over to the present day. The lower molecular weight plasma volume expanders do not significantly affect any of the commonly used crossmatching techniques. The situation in which there may be occasional difficulties relates to patients who have been on dextran infusion for several days and may have accumulated the larger molecular weight components which may have an effect on crossmatching. Difficulties in interpreting enzyme crossmatch techniques may occasionally occur. For practical purposes, the two most valuable crossmatching techniques (saline and Coombs') are not significantly affected by any of the currently available plasma volume expanders.
